Zai Lab under pressure over clinical results and rival drugs 产品增长疲软核心临床进展不顺 再鼎医药遭遇挑战
Shares in the Chinese biopharma firm have been pounded by disappointing trial results for a cancer drug and sluggish sales of its existing products. 市场用脚投票的背后，是再鼎医药核心产品增长疲软与研发管线受挫的双重困境。
Bamboo Works (official website) provides news on Chinese companies listed in Hong Kong and the United States, with a strong focus on mid-cap and also pre-IPO companies.